India Cancer Diagnostics Test Market, Test Price By Indication & Future Outlook 2028

August 2024 | 120 pages | ID: IC67741EB1A9EN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

India Cancer Diagnostics Test Market, Test Price By Indication & Future Outlook 2028 Report Offering:

• India Cancer Diagnostic Tests Market Opportunity: > US$ 250 Million
• India Cancer Diagnostic Tests Market Current & Future Scenario
• Cancer Diagnostic Tests Market Business Models In India
• India Cancer Diagnostic Tests Market Size (2024 -2028) By Indications
• Cancer Diagnostic Tests Availability & Pricing By Indications, Labs/Hospitals & City
• Multiple Antigen Test Costs By Indications, Market & Labs/Hospitals
• Estimated Cancer Cases (2024 -2028) By Indication

The need for cancer diagnostic tests in India is both significant and urgent. With a population exceeding 1.4 Billion, the country faces unique challenges in providing comprehensive cancer care. Many cases are diagnosed at late stages due to a combination of factors including lack of awareness, limited access to healthcare facilities and financial constraints. Improved availability and accessibility of diagnostic tests could lead to earlier detection and, consequently, better treatment outcomes for patients across the country. India’s cancer diagnostic tests market is experiencing rapid growth, driven by the rising incidence of cancer in the country and increasing awareness about the importance of early detection. Cancer has become a major public health concern in India, with over 1 Million new cases diagnosed annually and around 900,000 deaths per year. This situation underscores the critical need for effective and accessible diagnostic tests across the nation.

Among the most prominent cancers in India are breast cancer, oral cancer, cervical cancer, lung cancer, colorectal cancer and stomach cancer. Each of these cancer types requires specific diagnostic test approaches, contributing to the complexity of the cancer diagnostic landscape in India.

A wide range of diagnostic tests are available for these cancers, including imaging tests such as X-rays, CT scans, MRI scans, PET scans and ultrasounds. Endoscopy procedures like colonoscopy, bronchoscopy and upper endoscopy are also commonly used. Biopsy methods, including fine-needle aspiration, core needle biopsy, and surgical biopsy, play crucial role in definitive diagnosis. Blood tests, such as complete blood count, tumor marker tests, and circulating tumor cell tests, are often employed for screening and monitoring. Additionally, specific tests like Pap smears and HPV tests for cervical cancer, and mammography for breast cancer screening, are essential components of cancer diagnostics in India.

The cancer diagnostic market in India is a collaborative effort involving both government and private players. Government institutions like the All India Institute of Medical Sciences (AIIMS) and the Tata Memorial Centre are pivotal in research, diagnosis and treatment, serving patients from various socioeconomic backgrounds. In the private sector, major hospital chains such as Apollo Hospitals, Max Healthcare and Fortis Healthcare are key players, alongside specialized diagnostic companies like Metropolis Healthcare, Dr Lal PathLabs and Vijaya Diagnostic Centre. Additionally, international companies like Siemens Healthineers, GE Healthcare and Philips Healthcare contribute advanced technologies and expertise to the Indian market. The burgeoning market has also witnessed the emergence of various startups across India such as OncoStem Diagnostics and PredOmix, which are bringing next generation expertise and tools in cancer diagnosis.

Along with these, domestic academic institutions and research organizations have also been key driving forces behind the tremendous innovation and development observed in the Indian cancer diagnostic tests market. The International Institute of Information Technology (IIIT), Hyderabad is one noteworthy example; in 2023, the institute announced the development of a screening tool for oral cancer. The tool was created in collaboration between iHub-Data at IIIT-H and INAI, an applied AI research center managed by IIIT-H, the Telangana government, Intel, and the Public Health Foundation of India.

The future of India’s cancer diagnostic tests market looks promising for companies seeking entry, with several factors contributing to this positive outlook. This predominantly includes government initiatives like the National Cancer Control Programme and the Ayushman Bharat Scheme, which are increasing focus on cancer prevention, early detection and treatment. Further, for companies looking to enter or expand in India’s cancer diagnostic marker, there is a growing emphasis on developing affordable solutions. Given the large population and diverse economic conditions in India, there is a significant opportunity for companies that can provide high quality, cost effective diagnostic tests. This focus on affordability, combined with the overall growth of the market, creates a favorable environment for both domestic and international players in the cancer diagnostics sector.

Contents

1. INDIA CANCER DIAGNOSTIC TESTS MARKET OVERVIEW

1.1 Current Market Scenario
1.2 Future Market Opportunities

2. INDIA CANCER DIAGNOSTIC TESTS MARKET BUSINESS MODELS

2.1 Hospitals
2.2 Private Diagnostic Labs

3. LUNG CANCER DIAGNOSIS IN INDIA

3.1 Market Overview
3.2 Tests Availability & Pricing

4. PROSTATE CANCER DIAGNOSIS IN INDIA

4.1 Market Overview
4.2 Tests Availability & Pricing

5. CERVICAL CANCER DIAGNOSIS IN INDIA

5.1 Market Overview
5.2 Tests Availability & Pricing

6. BREAST CANCER DIAGNOSIS IN INDIA

6.1 Market Overview
6.2 Tests Availability & Pricing

7. ORAL CANCER DIAGNOSIS IN INDIA

7.1 Market Overview
7.2 Tests Availability & Pricing

8. STOMACH CANCER DIAGNOSIS IN INDIA

8.1 Market Overview
8.2 Tests Availability & Pricing

9. PANCREATIC CANCER DIAGNOSIS IN INDIA

9.1 Market Overview
9.2 Tests Availability & Pricing

10. HEPATOCELLULAR CANCER DIAGNOSIS IN INDIA

10.1 Market Overview
10.2 Tests Availability & Pricing

11. COLORECTAL CANCER DIAGNOSIS IN INDIA

11.1 Market Overview
11.2 Tests Availability & Pricing

12. HEMATOLOGICAL CANCERS DIAGNOSIS IN INDIA

12.1 Market Overview
12.2 Tests Availability & Pricing

13. INDIA CANCER DIAGNOSTIC TESTS MARKET DYNAMICS

13.1 Market Drivers & Opportunities
13.2 Market Challenges & Restraints

14. COMPETITIVE LANDSCAPE

14.1 Aarthi Scans and Labs
14.2 Apollo Diagnostics (Apollo Health and Lifestyle Limited)
14.3 DNA Forensics Laboratory
14.4 DNA Labs India
14.5 Dr. Lal PathLabs
14.6 Fortis Healthcare Limited
14.7 Ganesh Diagnostic
14.8 Pathkind Labs
14.9 Tata Memorial Center
14.10 Vijaya Diagnostic Center
Table 1-1: Cancer Diagnostic Tests – Major Players by City
Table 3-1: Lung Cancer – CEA Antigen Test Costs (INR/US$), August’2024
Table 3-2: Lung Cancer – SCC-TA4 Antigen Test Costs (INR/US$), August’2024
Table 3-3: Lung Cancer – CA125 Antigen Test Costs (INR/US$), August’2024
Table 3-4: Lung Cancer – CYFRA 21 Antigen Test Costs (INR/US$), August’2024
Table 5-1: Cervical Cancer – CA19.9 Antigen Test Costs (INR/US$), August’2024
Table 5-2: Cervical Cancer – CA125 Antigen Test Costs (INR/US$), August’2024
Table 5-3: Cervical Cancer – CEA Antigen Test Costs (INR/US$), August’2024
Table 5-4: Cervical Cancer – CA15.3 Antigen Test Costs (INR/US$), August’2024
Table 6-1: Breast Cancer – CA15.3 Antigen Test Costs (INR/US$), August’2024
Table 6-2: Breast Cancer – CEA Antigen Test Costs (INR/US$), August’2024
Table 6-3: Breast Cancer – CA125 Antigen Test Costs (INR/US$), August’2024
Table 6-4: Breast Cancer – CA27.29 Antigen Test Costs (INR/US$), August’2024
Table 6-5: Breast Cancer – Ki-67 Antigen Test Costs (INR/US$), August’2024
Table 7 1: Oral Cancer – CA125 Antigen Test Costs (INR/US$), August’2024
Table 8-1: Stomach Cancer – CA 19.9 Antigen Test Costs (INR/US$), August’2024
Table 8-2: Stomach Cancer – CA 72.4 Antigen Test Costs (INR/US$), August’2024
Table 8-3: Stomach Cancer – CEA Antigen Test Costs (INR/US$), August’2024
Table 9-1: CA 19.9 Pancreatic Cancer Marker - Test Cost via MediFee by City (US$/INR), August’2024
Table 9-2: Pancreatic Cancer – CA19.9 Antigen Test Costs (INR/US$), August’2024
Table 9-3: Pancreatic Cancer – CEA Antigen Test Costs (INR/US$), August’2024
Table 10-1: Serum AFP - Test Cost via MediFee by City (US$/INR), August’2024
Table 10-2: Hepatocellular Cancer – Alpha Fetoprotein Antigen Test Costs (INR/US$), August’2024
Table 10-3: Hepatocellular Cancer – CEA Antigen Test Costs (INR/US$), August’2024
Table 10-4: Hepatocellular Cancer – PIVKA-2 Antigen Test Costs (INR/US$), August’2024
Table 10-5: Hepatocellular Cancer – Ferritin Antigen Test Costs (INR/US$), August’2024
Table 11-1: Colorectal Cancer – CA19.9 Antigen Test Costs (INR/US$), August’2024
Table 11-2: Colorectal Cancer – CEA Antigen Test Costs (INR/US$), August’2024
Table 12-1: Hematological Cancers – CD19 Antigen Test Costs (INR/US$), August’2024
Table 12-2: Hematological Cancers – CD22 Antigen Test Costs (INR/US$), August’2024
Table 12-3: Hematological Cancers – CD33 Antigen Test Costs (INR/US$), August’2024